Home » Stocks » FBRX

Forte Biosciences, Inc. (FBRX)

Stock Price: $30.96 USD 0.65 (2.14%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 409.54M
Revenue (ttm) n/a
Net Income (ttm) -49.24M
Shares Out 13.25M
EPS (ttm) -4.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $30.96
Previous Close $30.31
Change ($) 0.65
Change (%) 2.14%
Day's Open 30.83
Day's Range 29.58 - 32.49
Day's Volume 185,780
52-Week Range 17.90 - 53.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as ...

2 weeks ago - Business Wire

Investors need to pay close attention to for Forte Biosciences (FBRX) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as ...

3 weeks ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provides a general bus...

2 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general bus...

2 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provide...

4 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a ...

4 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Bioscien...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

5 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as re...

5 months ago - Business Wire

FB-401 is a unique approach to atopic dermatitis containing three strains of bacteria that have shown the ability to induce tissue repair and reduce inflammation. FB-401 may present efficacy and safety ...

7 months ago - Seeking Alpha

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as ...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provi...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 result...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offerin...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public o...

8 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FD...

9 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the c...

9 months ago - Business Wire

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc.

10 months ago - Business Wire

Forte Biosciences (NASDAQ: FBRX) shares are trading higher on Friday after getting two upgrades.

10 months ago - Benzinga

About FBRX

Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.

Industry
Biotechnology
CEO
Martin Duvall
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
FBRX
Full Company Profile

Financial Performance

Financial Statements